Insider Buying Stocks
EIKN is part of our Insider Buying Stocks list, indicating stock insiders are buying the stock.
EIKON THERAPEUTICS INC (EIKN) Stock Price & Overview
NASDAQ:EIKN • US2825641036
Current stock price
11.74 USD
+0.19 (+1.65%)
At close:
11.74 USD
0 (0%)
After Hours:
The current stock price of EIKN is 11.74 USD. Today EIKN is up by 1.65%. In the past month the price increased by 0.26%.
EIKN Key Statistics
1-Month Range8.58 - 12.16
Current EIKN stock price positioned within its 1-month range.
- Market Cap
- 635.604M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.18
- Dividend Yield
- N/A
EIKN Stock Performance
Today
+1.65%
1 Week
+10.65%
1 Month
+0.26%
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
EIKN Stock Chart
EIKN Stock Screens
EIKN currently appears in the following ChartMill screener lists.
EIKN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to EIKN.
Chartmill TA Rating
Chartmill Setup Rating
EIKN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to EIKN. While EIKN has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
EIKN Earnings
Next Earnings DateN/A
Last Earnings DateN/A
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
EIKN Forecast & Estimates
12 analysts have analysed EIKN and the average price target is 25.25 USD. This implies a price increase of 115.03% is expected in the next year compared to the current price of 11.74.
Analysts
Analysts78.33
Price Target25.25 (115.08%)
EPS Next Y-9.12%
Revenue Next YearN/A
EIKN Groups
Sector & Classification
EIKN Financial Highlights
Over the last trailing twelve months EIKN reported a non-GAAP Earnings per Share(EPS) of -6.18. The EPS decreased by -36.84% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-333.64M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.1% | ||
| ROE | -118.13% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-22.68%
Sales Q2Q%N/A
EPS 1Y (TTM)-36.84%
Revenue 1Y (TTM)N/A
EIKN Ownership
Ownership
Inst Owners22.9%
Shares54.14M
Float41.99M
Ins Owners2.82%
Short Float %7.89%
Short Ratio6.96
EIKN Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About EIKN
Company Profile
Eikon Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Millbrae, California and currently employs 384 full-time employees. The company went IPO on 2026-02-05. Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The firm has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.
Company Info
IPO: 2026-02-05
EIKON THERAPEUTICS INC
230 Harriet Tubman Way
Millbrae CALIFORNIA US
Employees: 384
Phone: 13026587581
EIKON THERAPEUTICS INC / EIKN FAQ
What does EIKN do?
Eikon Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Millbrae, California and currently employs 384 full-time employees. The company went IPO on 2026-02-05. Eikon Therapeutics, Inc. is a late-stage clinical biopharmaceutical company, which is focused on advancing a pipeline of potential therapies for patients with unmet medical needs. The firm has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.
What is the current price of EIKN stock?
The current stock price of EIKN is 11.74 USD. The price increased by 1.65% in the last trading session.
Does EIKN stock pay dividends?
EIKN does not pay a dividend.
What is the ChartMill rating of EIKON THERAPEUTICS INC stock?
EIKN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the ownership structure of EIKON THERAPEUTICS INC (EIKN)?
You can find the ownership structure of EIKON THERAPEUTICS INC (EIKN) on the Ownership tab.